|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 11400 Rockville Pike |
Address2 |
|
City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Kelly Corredor |
Date | 10/16/2020 8:08:46 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.
Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.
Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019.
Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers.
Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.
Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.
Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction.
Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system.
Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy.
Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes
Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings
Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19
Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose.
Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.
Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).
Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19
Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.
Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.
Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.
Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.
Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.
Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.
Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction.
Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package
Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.
Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance
Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.
Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.
Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019.
Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers.
Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.
Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.
Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction.
Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system.
Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy.
Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes
Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings
Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19
Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose.
Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.
Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).
Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19
Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.
Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.
Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.
Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.
Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.
Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.
Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction.
Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package
Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.
Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance
Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.
Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.
Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019.
Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers.
Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.
Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.
Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction.
Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system.
Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy.
Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes
Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings
Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19
Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose.
Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.
Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).
Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19
Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.
Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.
Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.
Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.
Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.
Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.
Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction.
Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package
Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.
Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance
Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.
Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.
Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019.
Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers.
Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.
Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.
Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction.
Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system.
Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy.
Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes
Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings
Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19
Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose.
Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.
Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).
Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19
Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.
Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.
Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.
Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.
Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.
Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.
Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction.
Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package
Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.
Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance
Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.
Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.
Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019.
Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers.
Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.
Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.
Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction.
Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system.
Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy.
Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes
Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings
Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19
Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose.
Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.
Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).
Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19
Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.
Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.
Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.
Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.
Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.
Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.
Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction.
Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package
Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.
Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance
Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.
Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.
Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits. Advocated for its inclusion in the Lower Health Care Costs Act of 2019.
Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn. This bill is not specific to mental health, but it would provide significant stability to those patients and providers.
Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.
Supported HR 4974/S 4640: the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.
Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction.
Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system.
Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy.
Supported HR 7593/S 4103, the TREATS Act, that would increase the use of telehealth for substance use disorder treatment, and for other purposes
Advocated for at least $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19, as well as direct funding from SAMHSA to opioid treatment programs and qualified practice settings
Advocated for an increase in the Federal Medical Assistance Percentage for Medicaid as a result of COVID-19
Supported the Improving Medicaid Programs Response to Overdose Victims and Enhancing (IMPROVE) Addiction Care Act which would require state Medicaid programs to use their existing drug utilization review (DUR) programs to increase access to addiction treatment and boost safeguards for those on Medicaid who have experienced a non-fatal, opioid-related overdose.
Opposed passage of H.R. 884 / S. 2772, the Medicare Mental Health Access Act, which would change the definition of physician under the Medicare program to include clinical psychologists.
Supported the Dr. Lorna Breen Health Care Provider Protection Act (S.4349). The legislation would greatly reduce and prevent suicide and mental and behavioral health conditions among health care professionals.
Submitted comments on the Center for Medicare and Medicaid Services (CMS) Value in Opioid Use Disorder Treatment (Value in Treatment) Demonstration design. The 4-year demonstration program was authorized by section 6042 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act).
Supported additional research funding for NIAAA to study alcohol use related to the impact of COVID-19
Submitted comments on the proposed 2021 Medicare Physician Fee Schedule (MPFS). Comments stressed the importance of the Centers for Medicare and Medicaid Services altering the MPFS to expand access to treatment for as many beneficiaries suffering from substance use disorder (SUD) as possible by introducing new codes for telehealth, expanding the range of eligible disorders for the billing of certain bundled payments, and empowering ED clinicians through the creation of a new code.
Submitted its response to the Centers for Medicare and Medicaid Services (CMS) Request for Information (RFI) on Electronic Prescribing of Controlled Substances (EPCS). The RFI solicited feedback from stakeholders about whether CMS should include exceptions to the electronic prescribing of controlled substances and under what circumstances, and whether CMS should impose penalties for noncompliance with this mandate in its rulemaking, and what those penalties should be.
Submitted response to CMS supporting EPCS as a way to assure quality and reduce errors and fraud in the transmission of prescriptions from the prescribing health care practitioner to the dispensing pharmacist but recommending CMS consider the financial impact of this requirement on small practices that do not yet have electronic systems in place that allow for EPCS, and extend the waiver timeline as well as provide additional resources or incentives for these practices to adopt such technology.
Submitted comments on the Department of Labors (DOL) proposed update to the 2020 MHPAEA Self-Compliance Tool and commended DOL for the updates to the Self-Compliance Tool, while offering several detailed recommendations to clarify and strengthen the tool.
Urged Senate leadership to include $58 million for syringe services programs (SSPs) and other harm reduction service providers in the next COVID relief package.
Supported H.R. 7286, the Quit Because of COVID-19 Act. This legislation would ensure that all Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to the full array of evidence-based tobacco cessation treatments.
Sent a letter to the Secretary of Health and Human Services, Alex Azar, requesting his support for a waiver of at least two years of the Health and Human Services (HHS) Office of the Inspector General (OIG) interpretation of the Anti-Kickback Statute and Civil Monetary Penalties as applied to the implementation of contingency management for the treatment of addiction.
Supported includsion of S. 348, the Resident Physician Shortage Act, in the next COVID supplemental package
Supported House Resolution 1057 that would express the sense of the House of Representatives that investments in mental health care and substance use disorder care are necessary to address the high prevalence of those suffering from behavioral health conditions. It also recognizes the need for health care reform to integrate mental health care and substance use disorder treatment in the health care system.
Supported HR 7859, the Stregthening Behavioral Health Supports for Schools Act, that would establish in the Substance Abuse and Mental Health Services Administration a Center for School Behavioral Health Technical Assistance
Informational discussions with CMS regarding coverage of digital therapeutics for addiction treatment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |